EFPIA welcomes EMA guidelines

EMA sets clear rules for drug firms seeking clinical data redactions

By Gareth Macdonald

- Last updated on GMT

EMA clear on clinical trial data redactions
EMA clear on clinical trial data redactions

Related tags Pharmaceutical industry

Drugmakers seeking to stop “commercially confidential information” being made public in trial reports will need to demonstrate the likely economic harm publishing it would cause says the EMA.

The European Medicines Agency (EMA) made the comments in guidelines​ designed to help marketing authorization holders comply with its policy​ on trial data dissemination.

The document – published on March 2​ – details how drug firms should submit clinical reports, how they should make patient-level data anonymous and when they can ask for commercially confidential information to be redacted.

Clinical trial data redaction is a controversial subject. The agency has faced both challenges​ from companies concerned sharing data would benefit rivals and criticism from European Ombudsman Emily O’Reilly​ about information it has allowed to be omitted to date.

In the guidance the EMA stresses that “the vast majority of the information contained in clinical reports is not considered CCI (commercially confidential information).​” It also warned that drugmakers should not routinely make redaction requests every time the submit a study.


Instead, the agency said “redaction proposals based on grounds of CCI must be backed up by the applicant/MAH with a specific and clear justification.”

The justification must specify the precise information, set out how it is innovative and “explain how the disclosure of the information concerned would undermine the applicant’s/MAH’s legitimate economic interest.”

Drug companies will not be able to seek redactions for information that is already publically available, common knowledge or if its publication is in the public interest.

The first set of reports is due to be published in September 2016.

Industry backing

Drug industry group EFPIA told us: "We welcome the publication of the guidance by the EMA, as this now clarifies expectations of companies and allows them to progress activities to implement EMA’s Policy 0070. 

"We also welcome the fact that EMA has taken on board some of the feedback provided by industry during its consultations in 2015, such as allowing companies some flexibility in the format of presentation of redacted clinical study reports. 

EFPIA added that: "As is acknowledged in the guidance, this is a new undertaking: the initial operational implementation will be a learning process, so we can expect that challenges and questions will arise.  We look forward continued cooperation with the EMA to ensure that their Policy is implemented in the most efficient manne​r."

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more